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Indirect modulation
AMPAR activity lowers the threshold of NMDAR activation by
bringing the resting potential of the postsynaptic neuron to more
positive values, encouraging the opening of and promoting LTP.
Consequently, AMPAR positive allosteric modulators hold great
promises as cognitive enhancers. The most remarkable ones are
ampakines, which are able to freely cross the blood-brain
barrier and directly interact with AMPARs at the CNS, increasing
excitatory transmission.
Mechanism of action
Ampakines enhance current flow by slowing receptor’s dynamics
(desensitization and deactivation), hence prolonging its open
channel state. Remarkably, this effect only affects the receptors
activated by endogenously released glutamate, therefore
enhancing them in an activity-dependent manner, which
combined with the absence of targets outside the CNS permits to
obtain a positive modulation at a reduced dose hence avoiding
the side effects that will produce excessive activation.
Other beneficial effects
• Increased brain derived neurotrophic factor levels, which is 
known to chronically encourage induction and reinforce LTP 
consolidation.
• Enlarged cortical networks and increased nervous 
transmission for more complex computations.
• Provide a comprehensive and concise view of the pharmacological agents that are able to ameliorate cognition by
modulating glutamatergic transmission in the central nervous system
• Highlight the shared importance of the two aspects involved in smart drug development: Neurobiology and Bioethics
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Is it ethical?
References
• Cognitive enhancers have potential to improve life-quality of patients suffering impairments in mental functioning while also
benefiting healthy individuals
• Like every technology, they can be used well or poorly. In order to use them consciously, further research is needed.
• The final beneficial outcome may probably outreach the risks.
Stage Description Specifics
1 Literature search at Pubmed and ScienceDirect
as well as everyday journals for general
public’s opinion
Main search terms: Pharmacological cognitive enhancement,
Neuroenhancement and Glutamatergic transmission
2 Screening of the most accurate high-impact
articles, with special interest in reviews
Main sources: Nature Reviews Neuroscience, Neuron, Science and
Journal of Neuroscience
3 Selection of useful information and analysis of
bibliography
Comprehensive reading and study of scientific literature
4 Periodical check-up of new publications Recurrent research at online search engines
Glutamate is the most abundant excitatory neurotransmitter in the central nervous system and is known to play
a critical role in normal cognitive functioning by interacting with its receptors: metabotropic and ionotropic,
including NMDA, AMPA and kainate receptors. Currently the scope of scientific research is aimed to these last
ones, as they present a promising potential to treat cognitive impairment due to its role in promoting memory
formation in a process known as long-term potentiation (LTP).
LTP precisely strengths particular synapses upholding the development of intricate neural networks, the most
broadly accepted biological substrate of memory and complex thinking. Communication within and between
cortical networks is mainly mediated by glutamatergic transmission, then pharmacological agents that
potentiate glutamate action should provide a solid neurobiological base to the enhancement of cognition.
• Improvement of cognitive abilities in individuals (mentally impaired and healthy)
• Not a novel topic in society → + presence as technical breakthroughs come along
• Arduous task (no consensus measure and ambiguous definition)
• Based on the modulation of transient telencephalic networks 
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Introduction
Safety and Efficacy
•Modest positive effects
•Poor chronic administration data
Coercion
• Indirect (competition pressure)
•Direct (certain alertness 
demanding professions)
Fairness
•Equality of opportunity
•Honesty
•Authenticity
Reseach
•Truthful quality 
information
•Stimulate and 
fund new 
studies
Education
•Universally 
understandable
•Widely 
distributed
Use politics
•Professional 
organizations 
•No 
ideological/polit
ical influences
Legislation
•Novel legal 
framework
•New 
organizations
and regulatory
entities
Lines of  
action
A problem of  present day
Cognitive enhancer Neuromodulatory mechanism Cognitive functions
improved
Currently recommended
clinical use
Methylphenidate, 
amphetamine
Dopamine and noradrenaline 
reuptake inhibitors
Response inhibition, 
working memory, attention, 
vigilance
ADHD, wake-promoting
agent
Caffeine Non-selective adenosine
receptor antagonist
Vigilance, working memory, 
incidental learning
–
Nicotine Nicotinic cholinergic receptor 
agonist
Working memory, episodic 
memory, attention
–
Modafinil Unknown, but effects on 
dopamine, noradrenaline and 
orexin systems proposed
Working memory, episodic 
memory, attention
Wake-promoting agent
Atomoxetine, 
reboxetine
Noradrenaline reuptake
inhibitors
Response inhibition, 
working memory, attention
ADHD, depression
Donepezil, 
galantamine, 
rivastigmine (AChEI)
Blocks enzymatic breakdown of 
acetylcholine
Episodic memory, attention Alzheimer's disease, 
PDD, DLB
Memantine Noncompetitive, low-affinity, 
open channel blocker of the 
NMDA receptor
Episodic memory, attention Alzheimer's disease
The thing that I found
the most frustrating was
that their use of “study
drugs” actually worked
and some were
rewarded for it.
Female, 20, Dallas, USA
Unfair advantage?
At present day, relatively safe
cognitive enhancers with
moderate but clear effects in
healthy individuals are
available. The growing use of
these substances has become
relatively common among
college students and also
academia with strikingly high
prevalence, consequently
arising a series of ethical
issues that concern both public
opinion and normative
debate. Should healthy
individuals be able to use
cognitive enhancers?
Concluding remarks
LTP stands for long-term potentiation, an activity-dependent synaptic plasticity
mechanism in which synapses are strengthened by the generation of
molecular and structural changes that may last long periods of time,
eventually resulting in augmented efficacy of the neural connection.
In order to trigger LTP, two events must take place simultaneously:
In physiological conditions the first requirement is generally satisfied by
previous glutamate activation of AMPA receptors, which produces an
excitatory postsynaptic potential due to the generation of an inward sodium
current. This positively risen potential will facilitate the evacuation of the
magnesium ions that normally block the pore of the NMDA receptor, which
combined with the binding of presynaptic-delivered glutamate at the same
time will allow ions to flow through the channel, creating a strong net
calcium inward current. These calcium ions will act has key intracellular
messengers in an essential step for the LTP establishment phase.
1. Depolarization of the postsynaptic neuron
2. Release of glutamate by the presynaptic neuron
NMDAR 
activation
↓
LTP
Long-term potentiation
• Kinases involved in AMPAR phosphorylation →
• Enzymes participating in vesicle trafficking →
Signaling 
pathway
Stimulation of genes  → Protein synthesis  → Maintenance of LTP
Pharmacological modulation of  NMDAR activity
The NMDA receptor represents a prime target for cognitive
enhancement given its critical role in LTP and cognitive
processes. There exist multiple molecules that interact and
influence NMDAR functionally, therefore providing a fruitful
variety of targets to pursue enhancement. These substances
can be classified in two groups: indirect modulators and direct
modulators.
Direct modulation
1. Glycine
Glycine (or D-serine) acts as an essential co-agonist of the NMDAR at
glutamatergic synapses. Consequently, incrementing its levels augments the
activity of NMDARs. This increase can be achieved by two methods:
• A) Inhibition of the high affinity glycine transporters that prevent its
saturation in physiological conditions.
• B) Increase of D-serine extracellular levels by direct administration or
inhibition of its catabolizing enzyme, D-amino acid oxidase.
2. Antagonists
Under certain conditions NMDAR antagonists can result in cognitive
enhancement. This conception is based on the selective inhibition of
pathological activation or excitotoxicity while preserving ordinary activation.
• C) The most prominent one is memantine, a drug used as treatment of
Alzheimer’s disease described as a fast, voltage-dependent ion pore
channel blocker.
• D) It is also possible to increase extracellular magnesium concentration to
resist receptor’s overactivation.
3. Neurosteroids
E) Pregenenolone sulfate stands as the most promising neurosteroid for
enhancement. After binding the extracellular component of NMDAR, the
neurosteroid displays its intricate action as, even though the main outcome
is potentiation, it can also weaken receptor’s activity under certain
conditions. The most recognized hypothesis consists in that its predominant
facilitator role targets GluN2A/Glun2B subunit containing receptors whilst its
inhibitory action is focused at GluN2C/GluN2C receptors.
CX516
1. Collingridge GL. et al. The NMDA receptor as a target for cognitive enhancement. Neuropharmacology. 2013 Jan;64:13–26.
2. Lynch G. et al. Pharmacological enhancement of memory or cognition in normal subjects. Front Syst Neurosci. 2014 Jan;8:90.
3. Lynch G and Gall CM. Ampakines and the threefold path to cognitive enhancement. Trends Neurosci. 2006 Oct;29(10):554–62.
4. Lüscher C and Malenka RC. NMDA receptor-dependent long-term potentiation and long-term depression (LTP/LTD). Cold Spring Harb Perspect Biol. 2012
Jun;4(6).
5. Maher B. Poll results: look who’s doping. Nature. 2008 Apr 10;452(7188):674–5.
6. Sahakian BJ and Morein-Zamir S. Neuroethical issues in cognitive enhancement. J Psychopharmacol. 2011 Feb 8;25(2):197–204.
7. Schelle KJ. Et al. Attitudes toward pharmacological cognitive enhancement-a review. Front Syst Neurosci. 2014 Jan;8:53.
Aims and Methods
A) AS057278 B) D-serine
B) RG1678
C) Memantine
D) Magnesium-L-threonate
E) Pregnenolone sulfate
1 2 3
+ channel 
conductance
+ postsynaptic
receptor’s density
Table 1. Research methods used for the review.
Figure 1. NMDA receptor-dependent LTP schematic. (wiki.bethanycrane.com)
Figure 3. Effects of ampakines on AMPA receptor operation. (2)
Figure 4. Chemical structure
of NMDA receptor-targeted
cognitive enhancers.
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↑Neurosteroids
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Direct modulation
Indirect modulation
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Figure 2. Pharmacological modulation of NMDA receptor activity.
Figure 5. Current use of cognitive enhancers. (5) Figure 6. Cognitive enhancers are already a reality in academia. Figure 7. Ethical concerns and future pathway of cognitive enhancement.
Table 2. Substances commonly used as cognitive enhancers.
